Market OverviewFinlify
Price Date: 2026/06/15
AMAT logo

AMAT - Applied Materials Inc

The world's largest semiconductor equipment maker, supplying the deposition, etching, and inspection tools that chipmakers depend on to manufacture every generation of silicon.

BUYRelative StrengthCurrent data shows one of the stronger relative setups in Finlify's latest score snapshot.
BEATBEAT compares latest EPS results against analyst estimates.

Finlify Score

93.7 / 100

Data Quality

FULL

Penalty

0.0

Sector

Information Technology

Close Price

$585.78

+3.27%

52W Range

$154.47 - $569.95

Market Cap

$357.3B

+3.3%

Compared to previous day

2026 Q2 Revenue

$7.9B

+12.8%

Changes from last reporting quarter

2026 Q2 EPS

$3.51

Diluted shares

Analyst Rating

39 Buy7 Hold0 Sell

46 analysts in latest ratings feed

RSI

76.6

>70 overbought

2Y Range Position

97%

-2.3% from high / +373.4% from low

Beta

1.62

Relative to market benchmark

MACD

10.19

MACD line 36.09 / signal line 25.90

Fundamental Trend

Growth 92.5
Revenue QoQ+12.8%
Revenue YoY+11.4%
EPS QoQ+38.2%
EPS YoY+33.5%
Gross margin QoQ+0.9%
Operating margin QoQ+5.8%
Net margin QoQ+6.6%

Financial Health

Quality 94.2
Debt / equity0.22x
Debt ratio+13.0%
Cash / debt proxy1.20x
Cash / assets+15.6%

Data Quality

FULL
As of date2026-06-15
Latest statement2026-04-26
Penalty0.0
Missing dataNone

Valuation Reference

P/E63.65x
P/B9.03x
P/S15.70x
EV / EBITDA78.20x

Price Chart

Close price, two-year source window

Finlify Score

BUY

93.7 / 100

Relative Strength94.5 / 100
Accumulation & Volume93.3 / 100
Fundamental Trend92.5 / 100
Financial Quality94.2 / 100
Data Quality FULLNo penalty

Score History

Finlify Score and component trend

Financial Statements

Calendar year view. Figures are estimates only. For official figures, refer to the company website.

2026 Q22026 Q12025 Q42025 Q3
Revenue$7.9B+12.8%$7.0B+3.1%$6.8B-6.9%$7.3B+2.8%
Gross Profit$3.9B+14.9%$3.4B+5.2%$3.3B-8.3%$3.6B+2.2%
Operating Income$2.5B+37.8%$1.8B+7.0%$1.7B-23.3%$2.2B+3.0%
Net Income$2.8B+38.5%$2.0B+6.8%$1.9B+6.6%$1.8B-16.8%

Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.

AI Signal

Generated Jun 16, 2026

Finlify's signal for AMAT is BUY, supported by a strong Finlify Score of 93.7/100, which suggests a generally positive quantitative outlook for the asset.

Technical

The asset appears to exhibit strong technical momentum, with a Relative Strength score of 94.5/100 and an Accumulation / Volume score of 93.3/100. Its RSI(14) at 74.0 suggests it may be approaching overbought conditions, while recent performance shows significant gains, including a 20-day return of 28.8% and a 60-day return of 62.3%, with the stock currently at its 52-week high (0.0% distance).

Fundamentals

Fundamental analysis indicates a robust profile, with a Fundamental Trend score of 92.5/100 and a Financial Quality score of 94.2/100. However, valuation multiples appear elevated, with a P/E ratio of 63.6x, P/B of 9.0x, and P/S of 15.7x. The asset's Beta of 1.6 suggests higher volatility relative to the broader market, and it offers a modest dividend yield of 0.38%.

Macro Context

The current macro environment, characterized by CPI YoY at 4.3% and Core CPI at 3.0%, along with a 10Y Treasury Yield of 4.5%, suggests a potentially higher interest rate and inflationary backdrop. This environment may influence investor sentiment and valuation multiples for growth-oriented assets like AMAT, particularly given its higher beta.

Key Risks

  • Elevated valuation multiples, such as a P/E of 63.6x and P/S of 15.7x, may suggest the asset is priced for significant future growth, potentially limiting upside or increasing sensitivity to market corrections.
  • An RSI(14) of 74.0 indicates the asset may be in overbought territory, which could precede a short-term price consolidation or pullback.
  • A Beta of 1.6 suggests higher volatility, meaning the asset's price may experience larger swings than the overall market, potentially increasing risk in a downturn.